


[illegible]

Figure 1B: Retention of Activity by PEGylated Candida Uricase




## PEG-URATE OXIDASE CONJUGATES AND USE THEREOF

Williams, et al.

Appl. No.: 09/839946

Atty Docket: MVIEWD.1A2DV1

Figure 2A: Retention of Activity by PEGylated Porcine Uricase



## PEG-URATE OXIDASE CONJUGATES AND USE THEREOF

Williams, et al.

Appl. No.: 09/839946

Atty Docket: MVIEWD.1A2DV1

Figure 2B: Retention of Activity by PEGylated Porcine Uricase




Figure 3A: Retention of Activity by PEGylated PBC Uricase




Figure 3B: Retention of Activity by PEGylated PBC Uricase





Figure 4A:  
Retention of Activity by PEGylated Uricozyme® (*A. flavus* Uricase)




## PEG-URATE OXIDASE CONJUGATES AND USE THEREOF

Williams, et al.

Appl. No.: 09/839946

Atty Docket: MVIEWD.1A2DV1

Figure 4B:  
Retention of Activity by PEGylated Uricozyme® (A. flavus Uricase)






## PEG-URATE OXIDASE CONJUGATES AND USE THEREOF

Williams, et al.

Appl. No. 09/839946

Atty Docket: MVIEWD.1A2DV1

Figure 5A: Retention of Activity by PEGylated Soybean Uricase




## PEG-URATE OXIDASE CONJUGATES AND USE THEREOF

Williams, et al.

Appl. No.: 09/839946

Atty Docket: MVIEWD.1A2DV1

Figure 5B: Retention of Activity by PEGylated Soybean Uricase



## PEG-URATE OXIDASE CONJUGATES AND USE THEREOF

Williams, et al.


Appl No.: 09/839946

Atty Docket: MVIEWD.123571

Figure 6: Deduced amino acid sequences of Pig-Baboon Chimeric (PBC) uricase, PBC uricase that is truncated at the amino and carboxyl terminals (PBC-NT-CT) and Porcine uricase containing the mutations R291K and T301S (PKS Uracase) (SEQ ID NO:3), compared with the porcine sequence (SEQ ID NO: 1) and baboon sequence (SEQ ID NO: 2)

Porcine	MAHYRNDYKK NDEFEFVRTG YGKDMIKVLH IQRDGKYHSI	40
PBC	porcine sequence 1-225 →	40
PBC-NT-CT	porcine sequence 1-219 →	34
PKS	porcine sequence 1-288 →	40
Baboon	MADYHNNYKK NDELEFVRTG YGKDMVKVLH IQRDGKYHSI	40
Porcine	KEVATSVQLT LSSKKDYLHG DNSDVIPTDT IKNTVNVLAK	80
PBC	porcine sequence →	80
PBC-NT-CT	porcine sequence →	74
PKS	porcine sequence →	80
Baboon	KEVATSVQLT LSSKKDYLHG DNSDVIPTDT IKNTVNVLAK	80
Porcine	FKGIKSITET AVTICEHFLS SPKHVIRAQV YVEEVPWKRF	120
PBC	porcine sequence →	120
PBC-NT-CT	porcine sequence →	114
PKS	porcine sequence →	120
Baboon	FKGIKSIEAF GVNICEYFLS SFNHVIRAQV YVEEIPWKRL	120
Porcine	EKNGVKHVHA FIYTPTGTHF CEVEQIRNGP PVIHSGIKDL	160
PBC	porcine sequence →	160
PBC-NT-CT	porcine sequence →	154
PKS	porcine sequence →	160
Baboon	EKNGVKHVHA FIHTPTGTHF CEVEQLRSGP PVIHSGIKDL	160
Porcine	KVLKTTQSGF EGFIKDQFTT LPEVKDRCA TQVYCKWRYH	200
PBC	porcine sequence →	200
PBC-NT-CT	porcine sequence →	194
PKS	porcine sequence →	200
Baboon	KVLKTTQSGF EGFIKDQFTT LPEVKDRCA TQVYCKWRYH	200
Porcine	QGRDVFPEAT WDTVRSIVLQ KFAGPYDKGE YSPSVQKTLY	240
PBC	porcine sequence →	240
PBC-NT-CT	porcine sequence →	234
PKS	porcine sequence →	240
Baboon	QGRDVFPEAT WGTIRDLVLE KFAGPYDKGE YSPSVQKTLY	240
Porcine	DIQVLTGQV PEIEDMEISL PNHYLNIDM SKMGLINKEE	280
PBC	baboon sequence →	280
PBC-NT-CT	baboon sequence →	274
PKS	porcine sequence →	280
Baboon	DIQVLSLSRV PEIEDMEISL PNHYFNIDM SKMGLINKEE	280
Porcine	VLLPLDNPYG RITGTVKRKL TSRL	304
PBC	baboon sequence →	304
PBC-NT-CT	baboon sequence →	295
PKS	porcine   ← baboon	304
Baboon	VLLPLDNPYG KITGTVKRKL SSRL	304

Figure 7: Serum Uricase Activity 24 Hours after Each PEG-Uricase Injection, Relative to the First Injection




## PEG-URATE OXIDASE CONJUGATES AND USE THEREOF

Williams, et al.

Appl. No.: 09/839946

Atty Docket: MVIEWD.1A2DV1

Figure 8: Inverse Relationship between Serum PEG-Uricase Activity and Uric Acid Levels in the Serum and Urine of a Uricase-Deficient Mouse




## PEG-URATE OXIDASE CONJUGATES AND USE THEREOF

Williams, et al.

Appl. No.: 09/839946

Atty Docket: MVIEWD.1A2DV1

Figure 9: Decreased Severity of Urine-Concentrating Defect  
in Uricase-Deficient Mice Treated with PEG-Uricase




## PEG-URATE OXIDASE CONJUGATES AND USE THEREOF

Williams, et al.

Appl. No.: 09/839946

Atty Docket: MVIEWD.1A2DV1

Figure 10: Decreased Severity of Nephrogenic Diabetes Insipidus  
in Uricase-Deficient Mice Treated with PEG-Uricase



## PEG-URATE OXIDASE CONJUGATES AND USE THEREOF

Williams, et al.

Appl. No.: 09/839946

Atty Docket: MVIEWD 1A2DV1

Figure 11:

**Decreased Severity of Uric Acid-Induced Nephropathy after Treatment with PEG-Uricase, as Visualized by Magnetic Resonance Microscopy**






Figure 12: Clearance from the Circulation of BALB/c Mice of PBC Uricase Tetramer and Octamer Coupled to 5-6 Strands of 10-kDa PEG/Subunit

